NO20014529L - Tetrahydropyranderivater og deres anvendelse som terapautiske midler - Google Patents

Tetrahydropyranderivater og deres anvendelse som terapautiske midler

Info

Publication number
NO20014529L
NO20014529L NO20014529A NO20014529A NO20014529L NO 20014529 L NO20014529 L NO 20014529L NO 20014529 A NO20014529 A NO 20014529A NO 20014529 A NO20014529 A NO 20014529A NO 20014529 L NO20014529 L NO 20014529L
Authority
NO
Norway
Prior art keywords
alkyl
hydroxy
alkoxy
fluoro
group
Prior art date
Application number
NO20014529A
Other languages
English (en)
Other versions
NO20014529D0 (no
Inventor
Simon Neil Owen
Eileen Mary Seward
Christopher John Swain
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906480.0A external-priority patent/GB9906480D0/en
Priority claimed from GBGB9924616.7A external-priority patent/GB9924616D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NO20014529D0 publication Critical patent/NO20014529D0/no
Publication of NO20014529L publication Critical patent/NO20014529L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser av formel (I) (D hvori R1, R2, R3, R4, R5, R9 og R10 betegner et utall av substituenter; R6 betegner hydrogen eller en d.4-alkylgruppe eventu- elt substituert med en hydroksygruppe; R7 betegner halogen, hydroksy, C2_4-alkenyl, N3, -NR^R12, -NRaCORb, -OSO2Ra, - (CH2)pNRa(CH2)qCOORb, CORa, COORa eller en femleddet eller seksleddet, nitrogenholdig, heteroaromatisk ring eventuelt inneholdende l, 2 eller 3 ytterligere heteroatomer valgt fra N, O og S, hvilken heteroaromatisk ring eventuelt er substituert ved enhver substi- tuerbar stilling med en substituent valgt fra =O, =S, halogen, hydroksy, -SH, CORa, C02Ra, -ZNR^R12, d-4-alkyl, hydroksy-Ci-4- alkyl, f luor-C1.4-alkyl, Ci_4-alkoksy, fluor-Ci-4-alkoksy eller Ci_4-alkoksy substi- tuert med en d_4-alkoksy- eller hydroksyl- gruppe; R8 betegner hydrogen, Ci_6-alkyl, f luor-Ci-s-alkyl, hydroksy, Ci-6-alkoksy eller hydroksy-d-6-alkyl; og n er O, l eller 2; eller et farmasøytisk aksept- abelt salt derav. Forbindelsene er av særlig anvendelse ved behandling eller forhindring av depresjon, angst, smerte, inflammasjon, migrene, emesis eller postherpetisk neuralgi.
NO20014529A 1999-03-19 2001-09-18 Tetrahydropyranderivater og deres anvendelse som terapautiske midler NO20014529L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9906480.0A GB9906480D0 (en) 1999-03-19 1999-03-19 Therapeutic agents
GBGB9924616.7A GB9924616D0 (en) 1999-10-18 1999-10-18 Therapeutic agents
PCT/GB2000/000977 WO2000056728A1 (en) 1999-03-19 2000-03-16 Tetrahydropyran derivatives and their use as therapeutic agents

Publications (2)

Publication Number Publication Date
NO20014529D0 NO20014529D0 (no) 2001-09-18
NO20014529L true NO20014529L (no) 2001-11-13

Family

ID=26315315

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014529A NO20014529L (no) 1999-03-19 2001-09-18 Tetrahydropyranderivater og deres anvendelse som terapautiske midler

Country Status (23)

Country Link
US (1) US6458830B1 (no)
EP (1) EP1165540B1 (no)
JP (1) JP2002540107A (no)
KR (1) KR20010113773A (no)
CN (1) CN1344264A (no)
AT (1) ATE247096T1 (no)
AU (2) AU746251B2 (no)
BG (1) BG105859A (no)
BR (1) BR0009127A (no)
CA (1) CA2367985A1 (no)
CO (1) CO5150225A1 (no)
CZ (1) CZ20013377A3 (no)
DE (1) DE60004504T2 (no)
EA (1) EA200100902A1 (no)
EE (1) EE200100491A (no)
ES (1) ES2203434T3 (no)
HU (1) HUP0200441A3 (no)
IL (1) IL144236A0 (no)
NO (1) NO20014529L (no)
PE (1) PE20001556A1 (no)
PL (1) PL350123A1 (no)
SK (1) SK13322001A3 (no)
WO (2) WO2000056727A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001785A1 (de) * 2000-01-18 2001-07-19 Boehringer Ingelheim Pharma NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
GB0020721D0 (en) 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
PE20020444A1 (es) 2000-09-22 2002-06-14 Merck & Co Inc Antagonistas de receptores de taquiquinina zwitterionica
US6906085B2 (en) 2001-01-17 2005-06-14 Merck Sharp & Dohme Ltd. Tetrahydropyran derivatives as neurokinin receptor antagonists
GB0121874D0 (en) * 2001-09-10 2001-10-31 Merck Sharp & Dohme Therapeutic agents
GB0217068D0 (en) * 2002-07-23 2002-08-28 Merck Sharp & Dohme Therapeutic agents
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
AU2003286389A1 (en) * 2002-11-29 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
JP2006519822A (ja) * 2003-03-07 2006-08-31 メルク シャープ エンド ドーム リミテッド タキキニン拮抗薬としてのテトラヒドロピラン化合物
US7589205B2 (en) * 2004-09-08 2009-09-15 Nycomed Gmbh 3-thia-10-aza-phenanthrene derivatives
JP2008521804A (ja) * 2004-11-30 2008-06-26 マリンクロッド・インコーポレイテッド ベンズフェタミンの結晶化方法
CA2605594A1 (en) * 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
CN100395242C (zh) * 2006-06-08 2008-06-18 华东理工大学 烷氧基萘和萘醌类吡喃碳糖苷化合物及其制备方法
DE102007010077B4 (de) * 2007-02-28 2010-04-08 RUHR-UNIVERSITäT BOCHUM [1,3]-Dioxane zur Modulation von GABAa-Rezeptoren
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
CA2883791A1 (en) * 2012-09-04 2014-03-13 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
MX2016015610A (es) 2014-06-06 2017-07-13 Flexus Biosciences Inc Agentes inmunorreguladores.
EP3215141A4 (en) 2014-11-05 2018-06-06 Flexus Biosciences, Inc. Immunoregulatory agents
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
WO2019156074A1 (ja) * 2018-02-06 2019-08-15 第一三共株式会社 アミノアルキル化合物
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301920D0 (en) * 1993-02-01 1993-03-17 Foundation For Ethnobiology Th Polycetylenes

Also Published As

Publication number Publication date
EA200100902A1 (ru) 2002-02-28
DE60004504D1 (de) 2003-09-18
CA2367985A1 (en) 2000-09-28
DE60004504T2 (de) 2004-06-24
BG105859A (bg) 2002-04-30
PE20001556A1 (es) 2001-01-13
EP1165540B1 (en) 2003-08-13
CO5150225A1 (es) 2002-04-29
HUP0200441A2 (hu) 2002-07-29
WO2000056727A1 (en) 2000-09-28
US6458830B1 (en) 2002-10-01
AU746251B2 (en) 2002-04-18
SK13322001A3 (sk) 2002-02-05
WO2000056728A1 (en) 2000-09-28
AU3304200A (en) 2000-10-09
NO20014529D0 (no) 2001-09-18
KR20010113773A (ko) 2001-12-28
EE200100491A (et) 2002-12-16
CN1344264A (zh) 2002-04-10
BR0009127A (pt) 2001-12-26
ES2203434T3 (es) 2004-04-16
IL144236A0 (en) 2002-05-23
EP1165540A1 (en) 2002-01-02
CZ20013377A3 (cs) 2002-02-13
HUP0200441A3 (en) 2002-09-30
JP2002540107A (ja) 2002-11-26
ATE247096T1 (de) 2003-08-15
AU3304400A (en) 2000-10-09
PL350123A1 (en) 2002-11-04

Similar Documents

Publication Publication Date Title
NO20014529L (no) Tetrahydropyranderivater og deres anvendelse som terapautiske midler
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
BRPI0110955B8 (pt) derivados de tropano composição farmacêutica, uso dos mesmos na fabricação de um medicamento bem como processo para a preparação dos mesmos.
NO20052493L (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
PE20060459A1 (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
NZ524559A (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
NO20090270L (no) Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
HUP0301773A2 (hu) Apomorfinszármazékok és alkalmazásaik
TR199902495T2 (xx) Bile�imler.
NO20063619L (no) Diarylmetylpiperazinderivater, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application